Quantum-Accelerated Recombinant Protein Drug Embedding Frameworks (QARPDEF)

Innovate UK在小企业研究计划（SBRI）下向位于牛津的中小企业Vorsus提供了财政支持，该公司位于量子计算的最前沿，专门从事量子应用开发。Vorsus拥有一支经验丰富的物理学家、计算科学家、工程师和商业领袖团队，他们利用量子力学的力量来解决复杂问题，在优化、量子模拟、和量子机器学习。来自Innovate UK的资金用于研究和研究利用量子计算的新兴力量，通过创造新的药物来治疗未知的疾病，疗方重组蛋白质药物（RPD）是利用基因工程技术制造的药物，由于其高精度和靶向性质，与小分子药物相比具有优势。这些药物特别难以发现和开发，但已经改变了一些慢性疾病的治疗，如糖尿病和一些癌症。Vorsus的目标是开发一个具有高度影响力的基于量子的RPD发现管道工具包，该工具包将在第二代量子计算硬件上运行。根据可行性研究的结果，可能会向Vorsus分配更多资金，以开发第一版工具包，用于授权给研究型制药公司。

Innovate UK, under the Small Business Research Initiative (SBRI), has awarded financial support to Vorsus, an SME based in Oxford, which operates at the forefront of quantum computing, specialising in quantum-enabled application development. Vorsus has a team experienced physicists, computational scientists, engineers and business leaders who are harnessing the power of quantum mechanics to solve complex problems, unlocking unprecedented possibilities in optimisation, quantum simulations, and Quantum Machine Learning.The funding from Innovate UK is for a study and research into using the emerging power of quantum computing to enhance public health by creating new medicines to diseases with no known cure. It also aims to reduce government healthcare expenses by optimising the production efficiency of existing treatments.Recombinant protein drugs (RPDs) are medications created using genetic engineering techniques, offering advantages over small molecule drugs due to their high precision and targeted nature. These drugs are particularly difficult to discover and develop but are already transforming the treatment of some chronic medical conditions, such as diabetes and some cancers. Vorsus aims to develop a highly impactful quantum-enabled RPD discovery pipeline toolkit which will operate on second-generation quantum computing hardware.Based on the outcome of the feasibility study, further funds may be allocated to Vorsus to develop the first version of the toolkit for licensing to research-based pharmaceutical companies.